Micellar delivery of flutamide via milk protein nanovehicles enhances its anti-tumor efficacy in androgen-dependent prostate cancer rat model

Pharmaceutical Research

Volumn 30, Issue 10, 2013, Pages 2654-2663

  Elzoghby, Ahmed O ^a   Helmy, Maged W ^b   Samy, Wael M ^a,c   Elgindy, Nazik A ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

^b Pharos University in Alexandria   (Egypt)

^c BEIRUT ARAB UNIVERSITY   (Lebanon)

Author keywords

anti tumor efficacy; casein micelles; hepatotoxicity; hydrophobic anti cancer drugs; prostate cancer; spray drying

Indexed keywords

ALANINE AMINOTRANSFERASE; CASEIN; FLUTAMIDE; MILK PROTEIN; PROSTATE SPECIFIC ANTIGEN;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG RESPONSE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; MALE; MICELLAR DELIVERY SYSTEM; MOLECULAR DYNAMICS; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROSTATE CANCER; RAT; SEMINAL VESICLE; ZETA POTENTIAL;

ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CASEINS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; FLUTAMIDE; MALE; MICELLES; NANOPARTICLES; PARTICLE SIZE; PROSTATIC NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SURFACE PROPERTIES;

EID: 84883883466     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1091-7     Document Type: Article

References (40)

1. Wirth MP, Hakenberg OW, Froehner M. Antiandrogens in the treatment of prostate cancer. Eur Urol. 2007;51:306-14.
2. Zuo Z, Tam YK, Diakur J, Wiebe LI. Hydroxypropyl-β-cyclodextrin flutamide inclusion complex. ii. Oral and intravenous pharmacokinetics of flutamide in rat. J Pharm Pharmaceut Sci. 2002;5:292-8.
3. Elgindy N, Elkhodairy K, Molokhia A, Elzoghby A. Lyophilization monophase solution technique for improvement of the physicochemical properties of an anticancer drug, flutamide. Eur J Pharm Biopharm. 2010;74:397-405.
4. Elgindy N, Elkhodairy K, Molokhia A, Elzoghby A. Lyophilization monophase solution technique for preparation of amorphous flutamide dispersions. Drug Dev Ind Pharm. 2011;37:754-64.
5. Elgindy N, Elkhodairy K, Molokhia A, Elzoghby A. Lyophilized flutamide dispersions with polyols and amino acids: preparation and in vitro evaluation. Drug Dev Ind Pharm. 2011;37:446-55.
6. Elkhodairy K, Samy W. Optimization and evaluation of micromeritic and release properties of high dose flutamide liquisolid systems. Lett Drug Des Discov. 2012;9:336-44.
7. Murthy RSR, Umrethia ML. Optimization of formulation parameters for the preparation of flutamide liposomes by 3(3) factorial 26-term logit model. Pharm Dev Technol. 2004;9:369-77.
8. Madhusudhan B, Rambhau D, Apte SS, Gopinath D. Oral bioavailability of flutamide from 1-o-alkylglycerol stabilized o/w nanoemulsions. J Disp Sci Technol. 2007;28:1254-61.
9. Jeevana JB, Sreelakshmi K. Design and evaluation of self-nanoemulsifying drug delivery system of flutamide. J Young Pharm. 2011;3:4-8.
10. Elgindy N, Elkhodairy K, Molokhia A, Elzoghby A. Biopolymeric microparticles combined with lyophilized monophase dispersions for controlled Flutamide release. Int J Pharm. 2011;411:113-20.
11. Elzoghby AO, Abo El-Fotoh WS, Elgindy NA. Casein-based formulations as promising controlled release drug delivery systems. J Control Release. 2011;153:206-16.
12. Elzoghby AO, Samy WM, Elgindy NA. Protein-based nanocarriers as promising drug and gene delivery systems. J Control Release. 2012;161:38-49.
13. Semo E, Kesselman E, Danino D, Livney YD. Casein micelle as a natural nanocapsular vehicle for nutraceuticals. Food Hydrocoll. 2007;21:936-42.
14. Bourassa P, N'soukpoe-Kossi CN, Tajmir-Riahi HA. Binding of vitamin A with Milk α- and β-caseins. Food Chem. 2013;138:444-53.
15. Esmaili M, Ghaffari SM, Moosavi-Movahedi Z, Atri MS, Sharifizadeh A, Farhadi M, et al. Beta casein-micelle as a nano vehicle for solubility enhancement of curcumin; food industry application. LWT-Food Sci Technol. 2011;44:2166-72.
16. Shapira A, Assaraf YG, Epstein D, Livney YD. Beta-casein nanoparticles as an oral delivery system for chemotherapeutic drugs: impact of drug structure and properties on co-assembly. Pharm Res. 2010;27:2175-86.
17. Bachar M, Mandelbaum A, Portnaya I, Perlstein H, Even-Chen S, Barenholz Y, et al. Development and characterization of a novel drug nanocarrier for oral delivery, based on self-assembled β-casein micelles. J Control Release. 2012;160:164-71.
18. Dufresne MH, Fournier E, Jones MC, Ranger M, Leroux JC. Block copolymer micelles - Engineering versatile carriers for drugs and biomacromolecules. In: Gurny R, editors. Saint-Priest: B.T. Gattefossé; 2003;96:87-102.
19. Le Garrec D, Gori S, Luo L, Lessard D, Smith DC, Yessine MA, et al. Poly(N-vinylpyrrolidone)-block-poly(D, L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation. J Control Release. 2004;99:83-101.
20. Elzoghby AO, Samy WM, Elgindy NA. Novel spray-dried genipin-crosslinked casein nanoparticles for prolonged release of alfuzosin hydrochloride. Pharm Res. 2013;30:512-22.
21. Zhen X, Wang X, Xie C, Wu W, Jiang X. Cellular uptake, antitumor response and tumor penetration of cisplatin-loaded milk protein nanoparticles. Biomaterials. 2013;34:1372-82.
22. Elzoghby AO, Helmy MW, Samy WM, Elgindy NA. Elgindy spray-dried casein-based micelles as a vehicle for solubilization and controlled delivery of flutamide: formulation, characterization, and in vivo pharmacokinetics. Eur J Pharm Biopharm. 2013. doi: 10.1016/j.ejpb.2013.01.005.
23. Bosland MC, Prinsen MK. Induction of dorsolateral prostate adenocarcinomas and other accessory sex gland lesions in male wistar rats by a single administration of N-Methyl-N-Nitrosourea, 7,12-Dimethylbenz(α) Anthracene, and 3,2-Dimethyl-4-Aminobiphenyl after sequential treatment with cyproterone acetate and testosterone propionate. Cancer Res. 1990;50:691-9.
24. Stephan C, Jung K, Lein M, Sinha P, Schnorr D, Loening SA. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol Biomark Prev. 2000;9:1133-47.
25. Dash R, Dmitriev I, Su ZZ, Bhutia SK, Azab B, Vozhilla N, et al. Enhanced delivery of Mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) improves therapeutic efficacy in low car prostate cancer cells. Cancer Gene Ther. 2010;17:447-56.
26. Kaczmarek E, Górna A, Majewski P. Techniques of image analysis for quantitative immunohistochemistry. Rocz Akad Med Bialymst. 2004;49:155-8.
27. Kadama Y, Yerramillia U, Bahadur A. Solubilization of poorly water-soluble drug carbamezapine in pluronic micelles: effect of molecular characteristics, temperature and added salt on the solubilizing capacity. Colloids Surf B Biointerfaces. 2009;72:141-7.
28. De Kruif CG, Zhulina EB. κ-Casein as a polyelectrolyte brush on the surface of casein micelles. Colloids Surf A. 1996;117:151-9.
29. Fritz HS, Ries K, Nik B, Wim CJH, Albert K, Mercedes L. Prostate-specific antigen: a surrogate endpoint for screening new agents against prostate cancer? Prostate. 2000;42:107-15.
30. Danquah MK, Zhang XA, Mahato RI. Extravasation of polymeric nanomedicines across tumor vasculature. Adv Drug Deliv Rev. 2011;63:623-39.
31. Danquah M, Li F, Duke III CB, Miller DD, Mahato RI. Micellar delivery of bicalutamide and embelin for treating prostate cancer. Pharm Res. 2009;26:2081-92.
32. Danquah M, Fujiwara T, Mahato RI. Self-assembling methoxypoly(ethylene glycol)-b-poly(carbonate-co-L-lactide) block copolymers for drug delivery. Biomaterials. 2010;31:2358-70.
33. Rubio J, Ramos D, López-Guerrero JA, Iborra I, Collado A, Solsona E, et al. Immunohistochemical expression of Ki-67 antigen, Cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur Urol. 2005;48:745-51.
34. Sanna V, Roggio AM, Posadino AM. Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co- caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies. Nanoscale Res Lett. 2011;6:260.
35. Longoria RL, Cox MC, Figg WD. Antiangiogenesis: a possible treatment option for prostate cancer? Clin Genitourin Cancer. 2005;4:197-202.
36. Moul JW, Merseburger AS, Srivastava S. Molecular markers in prostate cancer: the role in preoperative staging. Clin Prostate Cancer. 2002;1:42-50.
37. Ma Y, Cheng Q, Ren Z, Xu L, Zhao Y, Sun J, et al. Induction of IGF-1R expression by EGR-1 facilitates the growth of prostate cancer cells. Cancer Lett. 2012;317:150-6.
38. Bustos-Obregón E, Esponda P. Increase in apoptosis and of the stress protein HSP70 in the mouse epididymis produced by the antiandrogen flutamide. Int J Morphol. 2009;27:463-8.
39. Budihardjo L, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol. 1999;15:269-90.
40. Gong J, Chen M, Zheng Y, Wang S, Wang Y. Polymeric micelles drug delivery system in oncology. J Control Release. 2012;159:312-23.